Infections with Gram negative bacilli resistant to all antibiotics except colistin have become increasingly common. This is a worldwide problem, with substantial issues being noted in South America and Asia. No new antibiotic classes with activity against these resistant Gram negative organisms are likely to be commercially available in the next 5 years. Yet, the pharmacokinetics (PK) of the only remaining antibiotic option, colistin, were studied in the 1960s when many of the modern principles of antibiotic dosing were not known. The Product Information of the drug suggests dosing regimens which may not be optimal for the management of serious infections. Furthermore, many patients with multiply resistant Gram negative infections are critically ill requiring renal replacement therapy and the Product Information gives no recommendations for dosing in this scenario. Although most physicians refer to """"""""colistin"""""""", the only form available for intravenous use is sodium colistin methanesulfonate (CMS). In the body, CMS is partially hydrolyzed to colistin. CMS and colistin differ in their antibacterial and PK characteristics. We were the first to develop HPLC assays which can separately measure both CMS and colistin.
We aim to measure the levels of CMS and generated colistin in plasma in all patients and at the site of infection in patients with pneumonia (lung epithelial lining fluid) in a multicenter cohort of 238 patients. We will also measure the clearance of CMS and colistin in those patients in the cohort who are undergoing dialysis or continuous renal replacement therapy. We will determine outcome of these patients and correlate outcome with pharmacodynamic parameters such as the ratio of area under the plasma concentration-time curve:minimal inhibitory concentration (MIC) or peak concentration:MIC. The primary outcome measures will be bacteriologic and clinical response. Mathematical modeling techniques such as Monte Carlo simulation will be used to integrate the PK/PD and outcome data in order to establish optimal dosing regimens. Resistance or intolerance to CMS/colistin leaves physicians with no antibiotic options - therefore, we will secondarily explore the relationships between PK, treatment duration and patient characteristics on resistance to colistin or advent of toxicity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI070896-05
Application #
8141270
Study Section
Clinical Research and Field Studies of Infectious Diseases Study Section (CRFS)
Program Officer
Xu, Zuoyu
Project Start
2007-09-15
Project End
2014-08-31
Budget Start
2011-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2011
Total Cost
$779,639
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Han, Mei-Ling; Shen, Hsin-Hui; Hansford, Karl A et al. (2017) Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes. ACS Infect Dis 3:606-619
Nation, Roger L; Garonzik, Samira M; Thamlikitkul, Visanu et al. (2017) Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis 64:565-571
Lenhard, Justin R; Thamlikitkul, Visanu; Silveira, Fernanda P et al. (2017) Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity. J Antimicrob Chemother 72:1415-1420
Forrest, Alan; Garonzik, Samira M; Thamlikitkul, Visanu et al. (2017) Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients. Antimicrob Agents Chemother 61:
Nation, Roger L; Garonzik, Samira M; Li, Jian et al. (2016) Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform? Clin Infect Dis 62:552-558
Cheah, Soon-Ee; Bulitta, Jurgen B; Li, Jian et al. (2014) Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal 92:177-82
Velkov, Tony; Deris, Zakuan Z; Huang, Johnny X et al. (2014) Surface changes and polymyxin interactions with a resistant strain of Klebsiella pneumoniae. Innate Immun 20:350-63
He, Hui; Li, Ji-Chang; Nation, Roger L et al. (2013) Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J Antimicrob Chemother 68:2311-7
Lee, Hee Ji; Bergen, Phillip J; Bulitta, Jurgen B et al. (2013) Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 57:3738-45
Velkov, Tony; Soon, Rachel L; Chong, Pei L et al. (2013) Molecular basis for the increased polymyxin susceptibility of Klebsiella pneumoniae strains with under-acylated lipid A. Innate Immun 19:265-77

Showing the most recent 10 out of 43 publications